Breaking Finance News

Jefferies & Co announced Aclaris Therapeutics (NASDAQ:ACRS), boosting its stock price target to $31.00 today

Displaying a price of $24.60, Aclaris Therapeutics (NASDAQ:ACRS) traded 0.12% lower on the day. The last stock close is up 25.75% from the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. The company has registered a 50-day average of $20.46 and two hundred day average of $19.46. 50,659 shares of Aclaris Therapeutics exchanged hands, down from ann avg. trading volume of 64,933

Aclaris Therapeutics (NASDAQ:ACRS) had its target price increased to $31 by Jefferies & Co in an issued report issued Monday September 19 2016. The latest target price implies a possible upside of 0.26% based on the company’s last stock close price.

Recent Performance Chart:

Aclaris Therapeutics (NASDAQ:ACRS)

A total of 3 equity analysts have released a ratings update on ACRS. Zero rate the company a strong buy, 0 rate the company a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the company as sell with a consensus target of $26.33

With a market cap of $0.0, Aclaris Therapeutics has a P/E of 0 with a one-year low of $10.99 and a 52 week high of $33.88.

General Company Details For Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. The Company has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, and for specified dermatological conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *